Oncolytic Vaccinia Virus in Lung Cancer Vaccines
Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effec...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/2/240 |
| _version_ | 1827652367585116160 |
|---|---|
| author | Cao-Sang Truong So Young Yoo |
| author_facet | Cao-Sang Truong So Young Yoo |
| author_sort | Cao-Sang Truong |
| collection | DOAJ |
| description | Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be utilized in cancer vaccines. Non-small cell lung cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or cancer vaccines, since it has a high tumor mutational burden. In this review, we will summarize recent applications of VV in lung cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines. |
| first_indexed | 2024-03-09T20:54:29Z |
| format | Article |
| id | doaj.art-6b2b35452de64a2ea9edfa13f78587dd |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T20:54:29Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-6b2b35452de64a2ea9edfa13f78587dd2023-11-23T22:25:48ZengMDPI AGVaccines2076-393X2022-02-0110224010.3390/vaccines10020240Oncolytic Vaccinia Virus in Lung Cancer VaccinesCao-Sang Truong0So Young Yoo1BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, KoreaBIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, KoreaTherapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be utilized in cancer vaccines. Non-small cell lung cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or cancer vaccines, since it has a high tumor mutational burden. In this review, we will summarize recent applications of VV in lung cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines.https://www.mdpi.com/2076-393X/10/2/240vaccinia virusoncolytic virusnon-small cell lung cancercancer vaccineimmunotherapypersonalized vaccination |
| spellingShingle | Cao-Sang Truong So Young Yoo Oncolytic Vaccinia Virus in Lung Cancer Vaccines Vaccines vaccinia virus oncolytic virus non-small cell lung cancer cancer vaccine immunotherapy personalized vaccination |
| title | Oncolytic Vaccinia Virus in Lung Cancer Vaccines |
| title_full | Oncolytic Vaccinia Virus in Lung Cancer Vaccines |
| title_fullStr | Oncolytic Vaccinia Virus in Lung Cancer Vaccines |
| title_full_unstemmed | Oncolytic Vaccinia Virus in Lung Cancer Vaccines |
| title_short | Oncolytic Vaccinia Virus in Lung Cancer Vaccines |
| title_sort | oncolytic vaccinia virus in lung cancer vaccines |
| topic | vaccinia virus oncolytic virus non-small cell lung cancer cancer vaccine immunotherapy personalized vaccination |
| url | https://www.mdpi.com/2076-393X/10/2/240 |
| work_keys_str_mv | AT caosangtruong oncolyticvacciniavirusinlungcancervaccines AT soyoungyoo oncolyticvacciniavirusinlungcancervaccines |